Diabetes Testing Devices-FDA Releases New Guidance Documents

Alexander Gaffney of raps.org details the Food and Drug Administration’s (FDA) push for new development approaches for diabetes testing systems. FDA has typically not distinguished between prescription and non-prescription diabetes testing devices. In review of the guidance documents, it is clear that FDA wishes to address concerns regarding the potential sharing of devices, as well as cleanliness. To view Gaffney’s article, click here. To help address these concerns, FDA released two new separate draft guidances on January 6, 2014. To see both guidance documents, see the links below:

Life Science Accelerated

Pearl Pathways is a comprehensive life science product development services company. Every day we strive to provide our customers top quality service, unyielding ethics, and efficient services through our team of experts. Pearl Pathways supports biopharmaceutical, medical device, and diagnostic companies as well as life science service providers with clinical, regulatory, and quality compliance needs. Our full-service central IRB supports all aspects of human research.